An Early Phase 1 interventional study of Methenamine Hippurate 1g BD and Methenamine Hippurate 1g BD + Vitamin C 1g BD in Urinary Tract Infections, sponsored by University Hospitals of North Midlands NHS Trust. Not yet recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by University Hospitals of North Midlands NHS Trust · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Urinary Tract Infections with a site in United Kingdom — 7 open to participants now, 10 under way, none of them phase 3. Urinary Tract Infections · United Kingdom.
Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, this one is the 14th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2027, is one of 5 in phase 1, and was the 27th registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →7 of the 31 studies in Urinary Tract Infections with a site in United Kingdom are open now. Recruiting first, the newest first:
Queen's University, Belfast · Sites in United Kingdom
University College, London · Sites in United Kingdom
Ages 18+ · Women only
University of Southampton · Sites in United Kingdom
Ages 65+ · Healthy volunteers
Royal Free Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Infectopharm Arzneimittel GmbH · Sites in United Kingdom, Austria, Germany and 2 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 131 across 564 interventional studies indexed under Urinary Tract Infections.
Median enrollment 48 across the 17 interventional studies, 1,250 across the 14 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 31 have an industry lead sponsor. The 10 most frequent:
University Hospitals of North Midlands NHS Trust is the lead sponsor of 28 studies on the registry; 9 are open to participants now.
University Hospitals of North Midlands NHS Trust has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Urinary Tract Infections with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06824129QIAGEN Gaithersburg, IncClinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR | 2026-12 |
| NCT07698041Katherine FinlayRUTISS-Diary and RUTISS-65 Study | 2027-06-30 |
| NCT06710899University Hospitals of North Midlands NHS TrustVitamin C and Hiprex in rUTI | 2027-08 |
| NCT07202949University College, LondonA Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Urinary Tract Infections with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Methenamine Hippurate 1g BD for 6 months
Drug: Methenamine Hippurate 1g BD
Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
Drug: Methenamine Hippurate 1g BD + Vitamin C 1g BD
Methenamine 1g BD for 6 months
Drug: Methenamine Hippurate 1g BD
Methenamine Hippurate 1g BD for 6 months
Drug page: Methenamine hippurateStudies of Methenamine hippurateMethenamine hippurate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
Frequency of UTIs
The incidence of symptomatic UTI during each six-month treatment phase of either methenamine hippurate alone or methenamine hippurate plus vitamin C
Time frame: 24 months
Urine pH
Measurement of urine pH during each treatment phase
Time frame: 24 months
Start is estimated for Jan 2027; primary completion for Aug 2027, 7 months later.
Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methenamine hippurate
University Hospitals of North Midlands NHS Trust